Home / Market News / $ABVX
benzinga Corporate Catalyst Impact 65/100 ● neutral

Abivax To Present Seven Scientific Abstracts On Obefazimod, Lead Drug Candidate For Treatment Of Active Ulcerative Colitis At UEG Week 2026 Meeting

Sep 30, 2026, 8:16 PM UTC · Primary ticker $ABVX

Abivax announced it will present seven scientific abstracts on its lead drug candidate, obefazimod, for ulcerative colitis at UEG Week 2026. This includes data from Phase 3 trials, long-term Phase 2 follow-up, and preclinical research, providing an update on the drug's development progress.

Abivax is announcing upcoming presentations at a major gastroenterology conference, UEG Week 2026, detailing data on its lead drug candidate, obefazimod, for ulcerative colitis. This event is significant as it will provide updated information from ongoing Phase 3 trials (ABTECT Maintenance and Induction), long-term Phase 2 follow-up, and preclinical anti-fibrotic research. For Abivax, this is an opportunity to showcase positive data, potentially boosting investor confidence and attracting further interest in obefazimod. While not a direct data release, the announcement of these presentations creates anticipation and could lead to short-term positive sentiment if the abstracts hint at strong results, or long-term impact if the full presentations confirm efficacy and safety. The key opportunity for traders is to monitor the actual presentations for any new, impactful data that could significantly alter the drug's perceived market potential.

$ABVX positive Presenting key drug data
$FR positive Abivax's primary listing
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.